Roth Capital Pounds Table on Cytokinetics (CYTK) into AAN BENEFIT-ALS Presentation

Roth Capital is bullish on Cytokinetics (Nasdaq: CYTK) into the company's BENEFIT-ALS study at AAN on April 29th.

Analyst Joseph Pantginis commented, We believe the data represent a potential transformational event for the company, especially with prior data suggesting clinical benefit and improvement to ALS patients. We reiterate our Buy rating, $25 price target and recommend investors own the stock ahead of next weeks major catalyst.

Pantginis elaborates, We believe the data represent a potential transformational event for the company, especially with prior data suggesting clinical benefit and improvement to patients. This contrasts with the expected course of the disease where patients show an approximate one point decline in their ALSFRS-R scores monthly. Tirasemtiv is a small molecule activator of fast skeletal muscle troponin in sarcomeres. Multiple clinical studies have been completed, including 3 Phase II studies in ALS, and studies in myasthenia gravis and claudication. We previously had the opportunity to talk to the Principal Investigator of the study, Jeremy M. Shefner, M.D., Ph.D., Professor and Chair of the Department of Neurology at the Upstate Medical University at SUNY. Dr. Shefner stated very succinctly, in our opinion, that in 20 years of treating patients with ALS and various involvement with clinical studies, has not received so many positive anecdotes from other physicians regarding the potential of a drug and how their patients are performing, even on a blinded basis.

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $10.80 yesterday.

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Atlantic Union Bankshares (AUB) PT Lowered to $35 at Keefe, Bruyette & Woods
• General Motors (GM) PT Raised to $45 at Piper Sandler